Resumen de Full Disclosure.

• The author discusses access to pharmaceutical clinical trial data, focusing on efforts to increase transparency as of June 2014 and their impact on the medical field. Topics include drug companies' withholding of negative and inconclusive trial results, methods of sharing data such as through Web portals created by drug companies like GlaxoSmithKline and Pfizer, and regulatory legislation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency.